A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma
Latest Information Update: 18 Jun 2019
At a glance
- Drugs Toreforant (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 10 Aug 2018 Primary endpoint (Change from baseline in prebronchodilator forced expiratory volume in 1 second (preBD FEV1)) has not been met, according to results published in the Annals of Allergy, Asthma and Immunology.
- 10 Aug 2018 Results published in the Annals of Allergy, Asthma and Immunology.
- 30 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.